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Abstract: PURPOSE OF REVIEW: Lung transplantation has become an accepted therapy in infants,
children, and adolescents suffering from end-stage lung diseases, an impaired quality of life and reduced life
expectancy. The aim of this review is to highlight specific aspects of pediatric lung transplantation and to
give an update on recent findings. RECENT FINDINGS: Currently, over 100 lung transplant procedures
are performed in children annually worldwide. Long-term success is limited by availability of donor organs
and waitlist mortality pretransplant, and an increased infection risk because of immunosuppression, and
most importantly late complications, such as chronic lung allograft dysfunction, medication nonadherence,
and transition intricacies. SUMMARY: Specific aspects of pediatric lung transplantation will be reviewed
and an update on most recent developments in the management of pediatric lung transplant recipients
given.
DOI: https://doi.org/10.1097/mot.0000000000000630





Benoit, Tobias M; Benden, Christian (2019). Pediatric lung transplantation: supply and demand. Cur-
rent Opinion in Organ Transplantation, 24(3):324-328.
DOI: https://doi.org/10.1097/mot.0000000000000630
 Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.






Lung transplantation has become an accepted therapy in infants, children, and adolescents suffering from
end-stage lung diseases, an impaired quality of life and reduced life expectancy. The aim of this review is
to highlight specific aspects of pediatric lung transplantation and to give an update on recent findings.
Recent findings
Currently, over 100 lung transplant procedures are performed in children annually worldwide. Long-term
success is limited by availability of donor organs and waitlist mortality pretransplant, and an increased
infection risk because of immunosuppression, and most importantly late complications, such as chronic lung
allograft dysfunction, medication nonadherence, and transition intricacies.
Summary
Specific aspects of pediatric lung transplantation will be reviewed and an update on most recent
developments in the management of pediatric lung transplant recipients given.
Keywords
children, chronic allograft dysfunction, extracorporeal membrane oxygenation, lung transplantation,
pediatric, transition
INTRODUCTION
Lung transplantation in children has been under-
taken since the 1980s, and nowadays, pediatric lung
transplantation is considered as an accepted therapy
option in carefully selected children with end-stage
parenchymal and vascular pulmonary diseases, pro-
viding well-selected pediatric candidates a net sur-
vival benefit and improved health-related quality of
life [1–4].
The 2018 International Society for Heart and
Lung Transplantation (ISHLT) Thoracic Transplant
Registry Report shows that currently over 100 pedi-
atric lung transplants are performed annually world-
wide, and over 2400 procedures have been carried
out in children to date [5
&&
]. Nevertheless, the num-
ber of centers reporting pediatric lung transplants
has remained without significant change in the last
year (n¼44); themajority of centers have performed
less than 5 transplants annually [5
&&
,6]. Tradition-
ally, the centers performing pediatric lung trans-
plants were mostly located in North America,
Europe, and Australia, but reports of successful pedi-
atric lung transplants in Asian and South American
centers are promising [5
&&
,6–8].
Cystic fibrosis continues to be the most com-
mon primary indication for pediatric lung trans-
plantation, but indications vary considerably by
age group [5
&&
]. In infants, pulmonary hypertension
and surfactant disorders are themain indications. In
children between 1 and 10 years of age, cystic fibro-
sis and idiopathic pulmonary arterial hypertension
are the most frequent underlying diseases. In ado-
lescents (11–17 years), cystic fibrosis is still by far the
most common disease leading to lung transplanta-




Vital to comprehend that children undergoing
lung transplantation present a challenge as children
are not ‘just small adults’ [2,4]. The surgical approach
is likely more challenging, and effects of immuno-
suppression in the developing immune system of a
child, and psychosocial aspects, particularly in ado-
lescents, have to be taken into consideration [4,10].
REFERRAL AND LISTING
In general, all children with end-stage parenchymal
and vascular pulmonary disease on maximal medi-
cal therapy, a predicted life expectancy of less than
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2 years, and a poor quality of life should be referred
to a lung transplant center for transplant assessment
[2,11]. Timing of referral is similar to adult practice;
however, smaller children should particularly be
referred as early as possible because of expected long
waiting times for suitable donor organs [11].
At the assessment of every pediatric lung trans-
plant candidate, the child and the family require to
be appropriately informed and sufficiently edu-
cated. Even a child should be willing to commit
to the planned transplant operation and to consent
generally to the close postoperative long-term fol-
low-up needed. Child and family support is vital and
should be implemented prior to listing for trans-
plantation if not already set up [2,4].
Overall, adherence to medical treatment needs
to be evaluated prior to listing for lung transplanta-
tion. Nonadherence is a leading cause for the devel-
opment of chronic allograft dysfunction (CLAD)
and inferior long-term outcome posttransplant,
and in particular in adolescents, it remains a well-
known feature following transplantation across all
solid organ types [12].
As a general rule, contraindications in pediatric
lung transplantation are similar to adult practice, but
relative contraindications differ between centers [2].
EXTRACORPOREAL MEMBRANE
OXYGENATION AS BRIDGE TO LUNG
TRANSPLANTATION
Apart from long-term invasive ventilation, extracor-
porealmembrane oxygenation (ECMO) has the abil-
ity to serve as a bridge to transplant in selected
patients on the waiting list with rapidly advancing
respiratory failure before a suitable donor organ is
allocated [13,14]. In general, candidates for ECMO
as bridge to transplant should be in single-organ
failure with a good rehabilitation potential [11]. The
consensus document by the ISHLT Council on Pul-
monary Transplantation lists contraindication for
ECMO as bridge to transplantation such as septic
shock andmultiorgan failure that are also applicable
for pediatric candidates [11]. The consensus docu-
ment focuses predominantly on adults but contains
a section specifically addressing pediatric issues,
however, in the broader term.
The use of ECMO ideally in awake pediatric
candidates as bridge to transplant has recently
shown to have no negative impact on the postoper-
ative survival rates [2,6,14]. Pretransplant rehabili-
tation is particularly important in patients with
respiratory failure requiring ECMO. Lung transplant
outcomes in patients transplanted bridged on
ECMO were significantly better in patients who
were able to ambulate than those who were not
[15,16].
Nowadays, ECMO as bridge to transplant in
children is considered as a superior alternative to
long-time mechanical ventilation by most trans-
plant centers, taking potential complications of
the two methods into consideration. Nevertheless,
the role of ECMO in long-term bridging to trans-
plant remains to be clearly defined [17].
DONOR ACCEPTABILITY CRITERIA IN
PEDIATRIC LUNG TRANSPLANTATION
The ISHLT published donor acceptability criteria in
the past, predominantly based on the adult lung
transplant experience [18]. The major limit of lung
transplantation is the worldwide lack of suitable
donor organs. Strategies to address the shortage of
donor lungs include usage of so-called marginal
donor organs (or extended criteria donor organs),
organ donation after circulatory death with or with-
out ex-vivo lung perfusion as graft preparation pre-
operatively, and lung graft size reduction (i.e., lobar
lung transplants) [19–23]. The latter is of particular
interest in pediatric lung transplant candidates
because of the shortage of donor organs of smaller
children [21].
In the USA, donor organs are allocated through
the Organ Procurement and Transplant Network
(OPTN) governed by United Network for Organ
Sharing (UNOS). Within its authority, children less
than 12 years of age are listed according to a two-tier
priority system on the basis of medical urgency,
whereas patients greater than equal to 12 years are
assigned a lung allocation score (LAS) similar to
adult candidates [6]. The LAS, implemented in the
USA in 2005, seeks to allocate organs to those
KEY POINTS
 Pediatric lung transplants have successfully been
carried out in children of all age groups with
encouraging outcomes.
 To maximize postoperative outcomes, pediatric
lung transplant candidates have to be selected very
carefully.
 ECMO bridging to lung transplantation is to be
considered in pediatric lung transplant candidates at
experienced transplant centers.
 Lung graft size reduction is considered a useful tool to
overcome donor organ shortage in smaller children.
 Similar to adult lung transplantation, the development
of CLAD limits the success of pediatric
lung transplantation.
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patients who will benefit most from a lung trans-
plant and thus limit waitlist mortality [24]. Trans-
plant candidates with higher LAS receive higher
waiting list priority within geographical boundaries
and matched blood type [25]. The LAS was not
developed to be used in children and their data were
not included in its risk-prediction models [26
&
].
Therefore, the LAS models may not appropriately
weigh the mortality risk of certain variables that
have unique significance in pediatric patients [26
&
].
Mortality rates of pediatric patients on the wait-
ing list are higher for children aged 0–5 years of age
in comparison to older children, adolescents, and
adults, which raises the question if the allocation
system discriminates the youngest age group, espe-
cially when listed in adult transplant centers [27]. A
waitlist and transplant outcome analysis by Lancas-
ter et al. [26
&
] demonstrated that outcomes have
significantly improved across all age groups,
although the magnitude of benefit has been less
for children compared with adolescents and adults.
Pediatric lung transplant candidates have his-
torically suffered longer waiting times and higher
rates of waitlist mortality than adults [6]. Over the
years, lung allocation in children has undergone
several modifications to improve the access of chil-
dren to donor lungs. Since 2013, individual pediat-
ric candidates are allowed to participate in the LAS
under special circumstances [26
&
]. Besides, OPTN
has recently approved expanded sharing to direct
all lungs less than 18 years old to child candidates
less than 12 years old first within a certain geo-
graphic radius of 1000mi, seeking to maximize
the availability of appropriately sized pediatric
donor organs to pediatric candidates [25,26
&
]. Fur-
thermore, the access of small children to donor
organs was expanded by allowing ABO-incompati-
ble lung transplants in children less than 2 years of
age with low antibody titers and high wait list
priority [26
&
]. As with all forms of organ transplan-
tation, donor organ availability remains the major
limitation to providing lung transplants to listed
pediatric candidates.
MANAGEMENT OF PEDIATRIC LUNG
TRANSPLANT RECIPIENTS AND
POSTTRANSPLANT OUTCOME
Immunosuppressive treatment is the foundation to
prevent lung allograft rejection [28,29]. In general,
the majority of children undergoing lung transplan-
tation receive induction therapy, most commonly
in the form of an interleukin-2 receptor antagonist
(basiliximab) [30]. Similar to adults, children take
triple maintenance immunosuppression posttrans-
plant, typically a calcineurin inhibitor (nowadays
commonly tacrolimus), a cell-cycle inhibitor (now-
adays commonly mycophenolate mofetil), and cor-
ticosteroids [2,3,17]. In an effort to standardize
treatment regimens, the International Pediatric
Lung Transplant Collaborative has previously
agreed upon unified guidelines (Goldfarb S, personal
communication).
Infectious complications are common causes for
morbidity andmortality in pediatric lung transplant
recipients, accounting for almost 50% of deaths
during the first year after transplantation [2]. Chil-
dren following lung transplantation that are at high
risk for infections caused by cytomegalovirus (CMV)
– defined as positive recipient or donor serology –
get CMV prophylaxis [31,32]. However, current
practice among pediatric programs varies, even
though international consensus guidelines on the
management of CMV in solid organ transplant
recipients were published [31]. Furthermore, pulmo-
nary fungal infections pose a significant risk to
pediatric lung transplant recipients; recently pub-
lished pediatric data show a decreased 12-month
posttransplant survival [33,34]. Prevention strate-
gies are variable and center-specific, but voricona-
zole monotherapy was the most common regimen
in pediatric cohorts [35]. The ISHLT Infectious
Diseases Council has recently published guidelines
for the management of fungal infections in cardio-
thoracic organ transplant recipients [36]. The con-
sensus document focuses predominantly on adults
but contains a section specifically addressing issues
in pediatric lung transplant recipients; however,
very limited data exist to respond to any of the
questions related to antifungal prophylaxis and/or
treatment in pediatric lung transplant recipients;
thus, mostly center-specific management proto-
cols are applied [36].
Respiratory viral infections are very common
after lung transplantation, in particular, in children
and associated with decreased 1-year survival [37].
Sources are often siblings or peer groups [2]. To aim
to reduce the burden of vaccine preventable dis-
eases, children should be vaccinated prior to be
placed on the transplant waiting list. It is well
known that vaccinations are frequently incomplete
before transplantation in these severely unwell chil-
dren. National vaccination guidelines should be
followed; vaccination guidelines for pediatric lung
transplant patients are center-specific; no consensus
guidelines exist to the authors’ knowledge. Vacci-
nations of household contacts are also highly rec-
ommended [38].
Overall, survival after pediatric lung transplan-
tation is comparable to adults [5
&&
], although ado-
lescent lung transplant recipients have poorer
overall survival when compared with younger
Lung transplantation
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children and adults, with 15–19-year-old patients
experiencing the highest risk of death [39
&
]. Accord-
ing to the most recent ISHLT Thoracic Transplant
Registry Report, median survival in children after
lung transplantation was 7 years for patients trans-
planted in the recent era (2008–2016) [5
&&
].
As in adult lung transplantation, the develop-
ment of CLAD is the major hurdle to achieve better
overall survival also after lung transplantation in
children. Bronchiolitis obliterans syndrome (BOS),
the most common form of CLAD, is the leading
cause of death by 5 years following transplantation.
International clinical practice guidelines for the
diagnosis and management of BOS have recently
been published [40]. To date, no well-proven ther-
apy approach exists to successfully manage CLAD in
lung transplant recipients, both in adult and chil-
dren. Attempts include change/augmentation of
immunosuppression, and use of macrolides, extra-
corporeal photopheresis, and total lymphoid irradi-
ation [41,42
&&
]. Pediatric data do generally not exist.
The final option for advanced lung allograft failure
is lung retransplantation. Data on pediatric lung
retransplantation are limited, most cases performed
for CLAD-BOS and in predominantly older children
[5
&&
]. Based on limited published outcome data,
pediatric lung retransplants appear to be more suc-
cessful if retransplantation follows a minimum of
12months after primary transplantation in children
not requiring invasive ventilator support at the time
of retransplant. Children who suffer from second
organ failure are regularly precluded from retrans-
plant [43].
TRANSITION FROM PEDIATRIC TO ADULT
CARE SETTING
With improving outcomes in pediatric lung trans-
plantation, transition from pediatric to adult care is
more frequent. As transition is not a single but
rather a process of an adolescent lung transplant
recipient being transferred to adult care providers,
various aspects of other transitions of an adolescent
that take place simultaneously need to be looked at
(i.e., autonomy, cognition, sexuality, physical
appearance, self-identity, education) [44
&
]. Ideally,
transition should advocate self-care and decision-
making of the adolescent but also include parents/
caregivers, taking into account the adolescent’s
chronological age, physical, and cognitivematurity.
In general, transition is regarded of interest for both
pediatric and adult transplant care teams [44
&
]. To
the authors’ knowledge, no consensus on the appro-
priate time and execution of transition of adolescent
lung transplant patients to adult transplant services
exists; most commonly, the practice applied is
extrapolated from transition in cystic fibrosis
patients as this is to date the largest cohort of
lung-transplanted adolescents.
CONCLUSION
To sum up, pediatric lung transplants have success-
fully been carried out in children of all age groups,
including infants, with encouraging outcomes. Sim-
ilar to adult lung transplantation, the development
of CLAD remains the burden of lung transplantation
in children and adults restricting long-term success.
Potential pediatric candidates for lung transplanta-
tion should be referred early, assessed thoroughly,
and selected very carefully to maximize the overall
net survival benefit following pediatric lung trans-
plantation. Specific pediatric aspects of lung trans-
plantation are the shortage of suitable donor organs
for smaller children and psychosocial aspects of
adherence, in particular, in adolescents. Intricacy
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